Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;144(2):638-650.
doi: 10.1378/chest.12-2114.

WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension

Affiliations
Review

WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension

Sif Hansdottir et al. Chest. 2013 Aug.

Abstract

World Health Organization (WHO) group 2 pulmonary hypertension (PH) due to left-side heart disease (ie, heart failure or left-sided valvular heart disease) is the most common form of PH in western countries. Distinguishing patients with WHO group 2 PH, particularly the subset of patients with PH due to heart failure with preserved ejection fraction (HFpEF), from those with WHO group 1 pulmonary arterial hypertension (PAH) is challenging. Separating the two conditions is of vital importance because treatment strategies differ completely. Furthermore, therapies that are indicated for WHO group 1 PAH may be harmful in patients with WHO group 2 PH. We review the somewhat confusing PH nomenclature and the WHO classification system and rationale behind it. We then focus on left-side heart disorders that cause PH. An aging population and advances in the medical management of common cardiovascular disorders have caused the prevalence of heart failure to rise significantly, with more than one-half of patients having HFpEF. We review contemporary studies that focus on clinical and echocardiographic findings that help to distinguish HFpEF from PAH in the patient with PH. We discuss the typical, and sometimes atypical, hemodynamic profiles that characterize these two groups, review challenges in the interpretation of data obtained by right-sided heart catheterization, and highlight special maneuvers that may be required for accurate diagnosis. Finally, we review the largely disappointing studies on the use of PAH-specific therapies in patients with WHO group 2 PH, including the use of prostacyclins, endothelin receptor antagonists, and the more promising phosphodiesterase-5 inhibitors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Etiologies and subcategories of WHO group 2 PH. HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LVEDP = left ventricular end-diastolic pressure; mPAP = mean pulmonary arterial pressure; PCWP = pulmonary capillary wedge pressure; PH = pulmonary hypertension; PVH = pulmonary venous hypertension; PVR = pulmonary vascular resistance; TPG = transpulmonary gradient; WHO = World Health Organization; WU = Wood units.

Comment in

  • Passive pulmonary hypertension: more than hydrostatics.
    Arrigo M, Huber LC. Arrigo M, et al. Chest. 2014 Feb;145(2):413. doi: 10.1378/chest.13-1960. Chest. 2014. PMID: 24493517 No abstract available.
  • Response.
    Hansdottir S. Hansdottir S. Chest. 2014 Feb;145(2):413-4. doi: 10.1378/chest.13-2157. Chest. 2014. PMID: 24493518 No abstract available.
  • Pulmonary hypertension drugs were never properly tested in heart failure.
    Guglin M. Guglin M. Chest. 2014 Feb;145(2):420. doi: 10.1378/chest.13-2121. Chest. 2014. PMID: 24493528 No abstract available.
  • Response.
    Hansdottir S, Gehlbach BK. Hansdottir S, et al. Chest. 2014 Feb;145(2):420-1. doi: 10.1378/chest.13-2519. Chest. 2014. PMID: 24493529 Free PMC article. No abstract available.
  • Pulmonary hypertension.
    Jamous F. Jamous F. Chest. 2014 Feb;145(2):432-3. doi: 10.1378/chest.13-2359. Chest. 2014. PMID: 24493546 No abstract available.
  • Response.
    Hansdottir S, Gehlbach BK. Hansdottir S, et al. Chest. 2014 Feb;145(2):433. doi: 10.1378/chest.13-2694. Chest. 2014. PMID: 24493547 No abstract available.

References

    1. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med. 2007;28(1):233-241 - PubMed
    1. Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98(24):1805-1811 - PMC - PubMed
    1. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;541):S55-S66 - PubMed
    1. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888-894 - PubMed
    1. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913-933 - PubMed

Publication types

MeSH terms

Substances